TW202334150A - 新穎化合物 - Google Patents

新穎化合物 Download PDF

Info

Publication number
TW202334150A
TW202334150A TW111140009A TW111140009A TW202334150A TW 202334150 A TW202334150 A TW 202334150A TW 111140009 A TW111140009 A TW 111140009A TW 111140009 A TW111140009 A TW 111140009A TW 202334150 A TW202334150 A TW 202334150A
Authority
TW
Taiwan
Prior art keywords
acid
compounds
compound
formula
inhibitors
Prior art date
Application number
TW111140009A
Other languages
English (en)
Chinese (zh)
Inventor
歐文 戴維斯
羅伯特 赫爾德
馬汀 史托克利
Original Assignee
英商阿帝歐斯製藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商阿帝歐斯製藥有限公司 filed Critical 英商阿帝歐斯製藥有限公司
Publication of TW202334150A publication Critical patent/TW202334150A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111140009A 2021-10-21 2022-10-21 新穎化合物 TW202334150A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2115156.8 2021-10-21
GBGB2115156.8A GB202115156D0 (en) 2021-10-21 2021-10-21 Novel compounds

Publications (1)

Publication Number Publication Date
TW202334150A true TW202334150A (zh) 2023-09-01

Family

ID=78805918

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111140009A TW202334150A (zh) 2021-10-21 2022-10-21 新穎化合物

Country Status (24)

Country Link
US (2) US20240425511A1 (cg-RX-API-DMAC7.html)
EP (2) EP4419527A1 (cg-RX-API-DMAC7.html)
JP (2) JP2024539132A (cg-RX-API-DMAC7.html)
KR (1) KR20240099274A (cg-RX-API-DMAC7.html)
CN (2) CN119053600A (cg-RX-API-DMAC7.html)
AR (1) AR127431A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022374050A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233255A1 (cg-RX-API-DMAC7.html)
DK (1) DK4419526T3 (cg-RX-API-DMAC7.html)
ES (1) ES3008687T3 (cg-RX-API-DMAC7.html)
FI (1) FI4419526T3 (cg-RX-API-DMAC7.html)
GB (1) GB202115156D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20250334T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070568T2 (cg-RX-API-DMAC7.html)
IL (1) IL311922A (cg-RX-API-DMAC7.html)
LT (1) LT4419526T (cg-RX-API-DMAC7.html)
MX (1) MX2024004874A (cg-RX-API-DMAC7.html)
PL (1) PL4419526T3 (cg-RX-API-DMAC7.html)
PT (1) PT4419526T (cg-RX-API-DMAC7.html)
RS (1) RS66620B1 (cg-RX-API-DMAC7.html)
SI (1) SI4419526T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500123T1 (cg-RX-API-DMAC7.html)
TW (1) TW202334150A (cg-RX-API-DMAC7.html)
WO (2) WO2023067355A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202115156D0 (en) * 2021-10-21 2021-12-08 Artios Pharma Ltd Novel compounds
WO2025077896A1 (zh) * 2023-10-12 2025-04-17 上海湃隆生物科技有限公司 一种DNA聚合酶theta抑制剂及其应用
CN118084767B (zh) * 2024-04-02 2025-06-17 康龙化成手性医药技术(宁波)有限公司 一种外型-6-氟甲基-3-氮杂双环[3,1,0]己烷盐酸盐及其衍生物的合成方法
WO2025214463A1 (zh) * 2024-04-13 2025-10-16 正大天晴药业集团股份有限公司 含有三并环结构的化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10760081B2 (en) 2015-10-07 2020-09-01 New York University Compositions and methods for enhancing CRISPR activity by POLQ inhibition
EP4010080B1 (en) * 2019-08-09 2023-09-27 Artios Pharma Limited Heterocyclic compounds for use in the treatment of cancer
GB202115156D0 (en) * 2021-10-21 2021-12-08 Artios Pharma Ltd Novel compounds
GB202115158D0 (en) * 2021-10-21 2021-12-08 Artios Pharma Ltd Novel compounds
GB202115150D0 (en) * 2021-10-21 2021-12-08 Artios Pharma Ltd Novel compounds

Also Published As

Publication number Publication date
MX2024004874A (es) 2024-05-06
JP2024539132A (ja) 2024-10-28
CN118234728A (zh) 2024-06-21
SMT202500123T1 (it) 2025-05-12
EP4419526A1 (en) 2024-08-28
LT4419526T (lt) 2025-03-25
CN119053600A (zh) 2024-11-29
RS66620B1 (sr) 2025-04-30
AU2022374050A1 (en) 2024-05-02
JP2024542949A (ja) 2024-11-19
WO2023067356A1 (en) 2023-04-27
PL4419526T3 (pl) 2025-04-22
US20240425511A1 (en) 2024-12-26
EP4419526B1 (en) 2024-12-25
EP4419527A1 (en) 2024-08-28
HUE070568T2 (hu) 2025-06-28
WO2023067355A1 (en) 2023-04-27
KR20240099274A (ko) 2024-06-28
ES3008687T3 (en) 2025-03-24
CA3233255A1 (en) 2023-04-27
SI4419526T1 (sl) 2025-05-30
DK4419526T3 (da) 2025-02-17
PT4419526T (pt) 2025-02-03
US20260124214A1 (en) 2026-05-07
FI4419526T3 (fi) 2025-02-13
AR127431A1 (es) 2024-01-24
HRP20250334T1 (hr) 2025-06-06
GB202115156D0 (en) 2021-12-08
IL311922A (en) 2024-06-01

Similar Documents

Publication Publication Date Title
EP4010329B1 (en) Deuterated compounds for use in the treatment of cancer
US12358886B2 (en) Heterocyclic compounds for use in the treatment of cancer
US20240166623A1 (en) Novel process
US20230278989A1 (en) Isoindolinone inhibitors of the mdm2-p53 interaction and process for making them
EP4419526B1 (en) Heterocyclic compounds for use in the treatment of cancer
EP4676602A1 (en) Compounds targeting mutations in p53 and uses thereof
WO2020030925A1 (en) Heterocyclic substituted ureas, for use against cancer
WO2020030924A1 (en) Thiazoleureas as anticancer agents
HK40112378B (en) Heterocyclic compounds for use in the treatment of cancer
HK40112378A (en) Heterocyclic compounds for use in the treatment of cancer
WO2024218499A1 (en) Heterocyclic inhibitors of dna polymerase theta for the treatment of cancer
HK40076656A (en) Deuterated compounds for use in the treatment of cancer
HK40076656B (en) Deuterated compounds for use in the treatment of cancer